---
title: "Biodexa tops 50% enrollment in Serenta Phase 3 FAP trial of eRapa"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296356016.md"
description: "Biodexa Pharmaceuticals announced that enrollment in its Phase 3 Serenta trial for eRapa, targeting familial adenomatous polyposis (FAP), has surpassed the halfway mark. The company recruited 87 of the planned 168 subjects across 29 clinical sites in the U.S. and Europe. This progress signals a key step toward pivotal efficacy assessment and potential commercialization. Results have not yet been presented; the next milestone is a planned futility analysis."
datetime: "2026-08-19T12:31:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296356016.md)
  - [en](https://longbridge.com/en/news/296356016.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296356016.md)
generator: "portal-rs"
---

# Biodexa tops 50% enrollment in Serenta Phase 3 FAP trial of eRapa

-   Biodexa reported recruitment passed the halfway mark in its registrational Phase 3 Serenta trial of eRapa in familial adenomatous polyposis. \* Results have not been presented; the next readout is a planned futility analysis, with a later database lock to support final evaluation. \* The update signals progress toward a pivotal efficacy assessment, a key step toward potential commercialization in a rare gastrointestinal cancer risk condition. \* Enrollment reached 87 of 168 planned subjects, with recruitment running across 29 U.S. and European clinical sites. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190830PRIMZONEFULLFEED1001258320) on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BDRX.US](https://longbridge.com/en/quote/BDRX.US.md)

## Related News & Research

- [Biodexa wins Health Canada approval to expand Serenta Phase 3 FAP trial into Canada](https://longbridge.com/en/news/291145787.md)
- [Biodexa to issue Series M, N and O warrants with $2.85 exercise price pending shareholder approval](https://longbridge.com/en/news/291279347.md)
- [Nordex total voting rights rise to 236.9 million shares](https://longbridge.com/en/news/297534449.md)
- [Artisan Partners cuts Sodexo stake to 9.99% of capital](https://longbridge.com/en/news/297199254.md)
- [UBS raises Aixtron voting rights to 3.95% from 3.38%](https://longbridge.com/en/news/298007588.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**